Take stock of the top ten goals of mergers and acquisitions in the field of medical technology

In the first half of this year, under the influence of the COVID-19 epidemic, the merger and acquisition of medical technology companies did not surprise the industry. in the first six months of 2020, medical technology companies completed 57 deals, with an average size of $108 million, worth less than $2 billion, the lowest level in a decade, according to a report by
Evaluate Medtech.
, the outbreak of COVID-19 also changed the industry's wind to some extent, some companies are feng shui, some are in the doldrums ... In the second half of the year, as the outbreak was under control, the total value of the new deals barely exceeded $16 billion, the largest of which was the $12.5 billion acquisition of diagnostic equipment maker Qiagen by Seymru.
more importantly, the outlook for medical diagnostic and test equipment companies is brighter after investor shareholders saw that COVID-19 seemed to create testing needs that could never be met.
, PwC believes the COVID-19 pandemic could eventually trigger new deals in the industry.
pressure on the medical device industry may lead to significant consolidation in the future in order to remain competitive.
then, in the first week of August, there were two anomalies in three days: Siemens Medical Group's $16.4bn acquisition of Varian Medical Systems and Teladoc's $18.5bn acquisition of Livongo, the smart blood sugar management platform.
late September, Genomics research and technology company Illumina paid $8 billion for Grail, the star company for early cancer liquid biopsies.
the combined investment prices of the three companies not only dwarf the total value of other medical technology mergers and acquisitions in 2020, but also exceed the total value of the $29 billion in healthcare technology mergers and acquisitions in 2018, close to $49 billion in 2019.
, as Priceco said, the COVID-19 epidemic has created new deals, and the power and desire to drive them remains, so there could be a lot of acquisitions in the future."
, for example, Siemens acquired Valian to build a single cancer care platform using the latter's radiotherapy products, covering everything from screening and diagnosis to treatment delivery and rehabilitation.
, Teladoc's bid for Livongo reflects the growing importance of virtual healthcare platforms as the world adjusts to providing as few face-to-face interactions as possible.
medical technology companies other than telemedicies are also looking for their portfolios for COVID-19 by connecting devices and teletechnology.
Many of the top mergers and acquisitions of highly competitive medical technologies meet the specific requirements of the day - making medical technology more portable through artificial intelligence, sensors, cloud technology, and unique solutions that suppliers can go to patient locations, not patients.
the COVID-19 pandemic has changed the direction of the industry to some extent, sending companies that can provide diagnostic tests into the doldrums while others have fallen into the doldrums.
, for example, the company's molecular diagnostics sales rose 375 percent year-on-year in the last fiscal quarter, earning nearly $820 million from the sector alone.
but this growth was offset by a decline in revenues in other business units, including gynaecological examinations.
companies such as Abbott, BD, Roche and Somerset found themselves in a similar predicament.
, what kind of deal do they want as the tumultuous 2020 season ends and the year goes on, when top healthcare technology companies are still looking for deals in the market? What are the advantages and characteristics of the following 10 medical technology companies that have become hot targets for mergers and acquisitions? 1, Biobeat, through wearables, has developed a way to track human blood pressure without inflating the cuffs, using a light sensor similar to the one used in consumer goods to calculate heartbeats.
could make Biobeat a must-kill company in the healthcare industry.
apple now has a smartwatch that supports electrostomes, and this year Amazon introduced a health-focused smart device that tracks the wearer's tone and analyzes their emotional state.
but so far, one indicator they haven't mastered is blood pressure.
Biobeat products have a wealth of activity and fitness trackers.
remote monitoring technology has also been given new value because the COVID-19 pandemic has forced clinicians to minimize access to patients and retain their personal protective equipment.
when using a cloud-based system to examine vital signs, patients are no different in hospital corridors or anywhere in the country.
Biobeat's sensors, which also track blood oxygen levels, breathing frequency, heart output, body temperature and sweating, can act as disposable vital signs monitors for patients transported by hospital patients or first responders.
2, Butterfly Network Butterfly Network is building a cheap portable handheld sensor that plugs into a smartphone or tablet and can be used almost anywhere.
this approach not only gives Butterfly Network a place in 10 companies, but also attracts the hedge fund Glenview Capital Management, which recently agreed to buy Butterfly Network for $1.5 billion and list it in a deal that ends in the first quarter of 2021.
Butterfly Network's Point of Care iQ device has been approved in the United States for a variety of applications, including heart, abdominal, vascular and lung scans in adults and children, and even monitoring for pneumonia in COVID-19 patients.
the $2,000 system has also been used in several low-resourced regions around the world, including COVID-19 test centers, emergency departments, intensive care units, etc., to provide diagnostic imaging.
the company recently released a new version of its device, iQ Plus, and worked with the American College of Cardiology (ACC) to help establish point-of-care ultrasound as the standard practice for diagnosing heart disease.
3, Caption Health changed its name to Caption Health in October 2019, and the company has been approved by the FDA for two groundbreaking artificial intelligence-guided heart ultrasound programs and raised $53 million in round B financing to help launch its software.
the AI developer's goal is to make heart echo cardiac heart maps more accessible, and it provides software that guides medical personnel without any professional training to take appropriate steps to capture clear ultrasound images.
, Caption Health's artificial intelligence integrates Withson's 3200T portable system.
the FDA said the software could be used with other imaging systems with appropriate specifications.
is likely to be a reminder that larger manufacturers with more ultrasound devices will buy Caption Health and sell and use its software in a wider range of regions, including globally.
In addition, Caption Health's products are likely to have the greatest impact in acute environments such as emergency rooms and intensive care units, with patients with large chest pains and shortness of breath requiring front-line staff to assess the possibility of a heart attack as quickly as possible without waiting for a specialist.
according to the company, the FDA approved the new version just 25 days after re-applying for software approval in February to help clinicians assess heart complications from COVID-19.
Caption Health is the second company to receive such rapid FDA approval after Philips' portable and fixed-point ultrasound system and Eko's ECG-based algorithm screened patients for signs of myocardial weakness.
recently, the company received another $4.95 million from the Bill and Melinda Gates Foundation to apply the same technology to lung ultrasound scans, with the goal of screening potentially fatal cases of childhood pneumonia and COVID-19 patients in low-resource environments.
4, Caresyntax Caresyntax aims to surround the operating room with a data platform that touches almost every aspect of a person's operation.
ultimately make the hospital's most profitable operation safer for patients and better for providers.
automated and artificial intelligence programs, the company connects with hospitals, medical device suppliers and anaesthetic suppliers to reduce delays and allocate resources effectively.
it provides performance indicators on digital dashboards, partially using patient outcome data from electronic health records.
also offers its own modular workflow tools and a customized computer console with remote-controlled laser pointers to guide surgeons during surgery.
caretsyntax technology is now used in more than 7,000 operating rooms around the world, covering at least 9 million procedures per year.
same time, Caresyntax's telemedic services also found new value during the COVID-19 pandemic, allowing virtual medical teams and company sales representatives to participate in programs that limit virus exposure.
through the company's system, users can access electronic health records and click or plan to coordinate inventory.
all this could make Caresyntax a bigger player in OR analytics, like Oracle, and a broader product line.
but Caresentax itself is greedy.
December 2019, it acquired Syus, a well-known provider of cost analysis and operating software for hospitals.
the company has also established a partnership with Medtronic.
recently, Caretsyntax launched a new program to help hospitals restart alternative surgery after the COVID-19 pandemic.
the Guidance of the American College of Surgeons and the Peri-Surgical Registered Nurses Association, the company aims to provide customized versions of the reopening of operating rooms and the prioritization of certain procedures.
of Hyperfine Research's modern technology is that any product that can be scaled down and used will be smaller and easier to use.
for Hyperfine Research, its nuclear magnetic resonance (MRI) imaging equipment and products in this area can make it a major target for medical technology acquisitions.
MRI imaging machines are usually stored in basements or on the first floor of hospitals, supporting their unstoable quality and the cost of shielding radiation on the upper levels.
but hyperfine's wheel scanner, launched this year, is designed to move patients throughout the building as needed.
this Swoop scanner weighs about one-tenth the weight of a conventional MRI imager and can be installed in elevators without special shielding and can be operated through everyday power outlets.
's not just for convenience.
Hyperfine is promoting its head-scanning device as a complement to heavier MRIs, which are particularly useful for patients in intensive care and are a system that improves overall efficiency.
removing a seriously injured patient from the intensive care unit for scans is a logistical challenge and a medical risk, and it can take hours on an MRI machine.
a simple scanner, large machines can handle a large number of less urgent cases without interruption.
February, Hyperfine's device was approved by the FDA for the first time.
the technology will reach $51 billion over the next four years, according to the Evaluate Medtech business unit.
, it makes sense and value if your product has a complementary technology, especially one that can be used at a lower cost at more points.
6, ivWatchivWatch created a miniaturized one-time early warning system that detects complications from intravenous drugs, including mis-positioned needles that leak the drug into surrounding tissues.
technology could make ivWatch an attractive company, especially for large companies that want to expand remote monitoring services or operate inpatient management and clinical workflow tools.
SmartTouch optical sensor patch approved by the FDA in July covered the infusion site, with the aim of alerting clinicians hours before an overflowing liquid was detected visually or tactilely.
the system for people of all ages, it complements the company's larger monitor, which is mounted on the patient's intravenous electrode and measures volume changes.
ivWatch estimates that there are 46 million intravenous intravenous infusions in the United States each year, nearly a quarter of which are caused by fluid leakage and penetration.
, ivWatch has expanded its international patent portfolio and issued new patents for its trademarks and intellectual property, which could make acquisitions more likely.
's latest patents in Europe, Japan and Australia cover core technologies used to distinguish between patient movement and intravenous fluid leakage into tissues, reducing the number of false alarms and allowing patients to move freely while being monitored.
7, Scanwell Health in late 2019, Scanwell Health introduced a smartphone-driven test (approved by the FDA) that allows people to check for urinary tract infections (UTI) at home and pair them with telemedican platforms to quickly contact prescription doctors